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2 Abstract 
Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia, and it is responsible 
for increased mortality and a reduced quality of life. Its prevalence is rapidly 
increasing. Catheter ablation has emerged during the past decade as a promising 
treatment option for paroxysmal and non-paroxysmal AF patients. We investigated 
various aspects of catheter ablation for AF, particularly in non-paroxysmal AF, with 
the aim of improving the safety and efficacy of such procedures. 
 
Aims and methods 
The patients enrolled in these studies were burdened by symptomatic, drug-refractory 
AF. Non-paroxysmal AF was the clinical arrhythmia in the majority of the 
individuals. All patients underwent an electrophysiological study and subsequently an 
ablation procedure that included pulmonary vein isolation and in selected cases, 
complex fractionated electrogram (CFE) ablation. The first study aimed to assess 
long-term outcomes in a population of exclusively non-paroxysmal AF patients who 
were followed up regularly for an average of 40 months. In the second study we 
investigated the effects of flecainide on the distribution and extension of CFE areas. 
For this purpose, two separate CFE maps (before and after flecainide administration) 
were created and compared. In the third study we assessed the correlation between 
catheter-tissue contact force and impedance fall. Qualified ablation points were 
selected and the corresponding contact force and impedance fall data were retrieved 
and analyzed. 
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Results and conclusions 
An approach consisting of pulmonary vein isolation and CFE ablation appears to 
provide favorable long-term outcomes in a high proportion of patients. Multiple 
procedures are often required to attain positive results. Although post-ablation atrial 
tachycardia frequently occurs, it may represent a step towards long-term success. 
Longer AF duration and female gender appear to predict a higher likelihood of 
procedural failure. 
Intraprocedural administration of flecainide in non-paroxysmal AF patients reduces 
the extension of CFE areas but preserves their original localization. The employment 
of a CFE-mean cut-off of 80 ms may facilitate the identification of stable CFE areas. 
The CFE areas that thus disappear may be functional and therefore may be an 
inappropriate target for ablation. 
Increasing degrees of catheter-to-tissue contact force lead to a larger impedance fall 
suggesting improved lesion formation. Under stable catheter conditions, a contact 
force greater than 5 g seems to create adequate lesions. However, a contact force 
beyond 20 g is associated with late impedance rise, and may be a warning of an 
increased risk of complications. 
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5 Introduction 
 
“Fibrillation, like flutter, may also on occasion be terminated in the auricle by cold or 
pressure very locally applied” 
Sir Thomas Lewis, 1925 
 
5.1  DEFINITION AND HISTORY 
Atrial fibrillation (AF) is a cardiac arrhythmia characterized by rapid and chaotic 
activation of the atria. As early as in the 17th century, Harvey observed ante-mortem 
chaotic motion in the atria (presumably representing AF) during open-chest 
examination of dogs1-3. A century later de Sénac correlated palpitations and irregular 
cardiac pulsation, two common AF symptoms, with the presence of abnormalities in 
the mitral valve (MV)1, 2. In the early 20th century, with the development of the 
electrocardiogram (ECG), AF began to be paid more attention4. An irregular 
ventricular response, the absence of P waves and presence of fibrillatory atrial activity 
are well established ECG criteria for the diagnosis of AF5.  
 
5.2  EPIDEMIOLOGY 
AF is the sustained cardiac arrhythmia that is most commonly encountered in clinical 
practice5, 6. In the western world, its prevalence is estimated at between 1% and 2% of 
the adult population, but it is significantly higher among individuals over 70 years of 
age5, 7.  
The annual incidence of AF was estimated by the Framingham Study to be 3.1/1000 
in males and 1.9/1000 in females aged 55 to 64 years8. When considering individuals 
of between 85 to 94 years of age, these figures increase to 38/1000 and 31/10008. 
Males are affected by more symptomatic forms of AF which also tend to appear 
earlier in life than in females5, 6, 8, 9. Data from the Rotterdam study estimated the 
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lifetime risk of developing AF at about 25% in individuals aged 40 or more9. Given 
the growing number of elderly people in the western society, the prevalence of AF is 
likely to increase in the near future10. Epidemiological projections estimate a rise in 
the number of AF patients of up to 12 million in the United States and 13 million in 
Europe by 203011, 12.  
The presence of idiopathic AF (lone AF) in an otherwise healthy subject accounts for 
around 10% of all AF patients13, 14. In the majority of the cases, AF is secondary to 
cardiac or non-cardiac conditions. Important cardiac conditions for the development 
of AF are valvular heart disease, ischemic heart disease, cardiac surgery, 
hypertension, myocarditis, and dilative and hypertrophic cardiomyopathy8. Important 
non-cardiac conditions for the development of AF are chronic obstructive pulmonary 
disease, hyperthyroidism, sleep apnea syndrome, acute infections, pulmonary 
embolism, binge drinking, obesity and diabetes15-18.  
 
5.3  PATHOPHYSIOLOGY 
Despite over a century of research, the precise mechanisms that start and perpetuate 
AF are incompletely understood. Like other cardiac arrhythmias, AF requires a trigger 
for its initiation and a substrate for its maintenance.  
In pioneering work performed during the 1950s, Moe et al. suggested that AF was 
maintained by multiple independent wavelets propagating randomly in a tissue with 
highly dispersed refractoriness19. This “multiple wavelet theory” postulated that a 
critical myocardial mass would be required for AF to be sustained indefinitely. 
Moe’s observations were confirmed almost 20 years later by the work of Allessie et 
al., which demonstrated simultaneous propagation of multiple independent wavelets 
in an acetylcholine dog model of AF20. The validity of this theory also found support 
in the positive outcomes of the Cox maze surgical procedure in which atrial lesions 
are created with the aim of compartmentalizing the left atrium (LA)21. The multiple 
wavelet theory is currently the most highly credited among clinical 
electrophysiologists.  
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At the beginning of the last century, Sir Thomas Lewis observed that the central 
excitation wave of AF showed a strong predilection for moving around a stable 
channel22. His statements, although criticized by his contemporaries, are nowadays 
being reconsidered. There is increasing evidence that, at least in some cases, AF 
propagates through stable circuits, also called rotors, as they rotate around an 
unexcited core23-27.  
 
5.3.1 Triggers 
In the 1990s, the availability of more sophisticated recording systems contributed to 
the search for the triggers of AF. Haïssaguerre first reported a series of three patients 
in whom AF episodes were triggered by an ectopic atrial focus28. The subsequent 
milestone work demonstrated that episodes of AF are consistently initiated by focal 
activity, mostly (94%) originating from the pulmonary veins (PVs). Ablation targeting 
these foci resulted in the disappearance of AF in 62% of the patients during the 
follow-up29. Apart from the PVs, additional sources of focal activity may be found in 
the LA body (particularly in the ligament of Marshall and MV annulus), the right 
atrium (RA) body (particularly in the crista terminalis, fossa ovalis and Eustachian 
ridge), superior and inferior caval veins and the coronary sinus (CS)29-35. Histological 
studies showed that the nature of increased PVs automaticity depends on the anatomy 
of the LA36, 37. Myocardial muscular sleeves extend deeply into the wall of the PVs, 
particularly in the left PVs36, 37.The intersection of myocardial and connective tissue 
from the PV wall determines anisotropic conduction, which creates the perfect 
substrate to enhance focal activity36, 38. These findings received remarkable resonance 
in the field of invasive electrophysiology and virtually launched the era of AF 
ablation.  
 
5.3.2 Substrate 
There is solid evidence that, with the perpetuation of AF, the atria undergo electrical 
and structural remodeling39-45. Electrical remodeling occurs within a few minutes of 
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the onset of AF and leads to a shortening of the refractory period and a reduction in 
conduction velocity39, 42-45. The changes that account for structural remodeling take 
place over a longer period of time and include hypertrophy of the myocytes, an 
increase in interstitial fibrosis, changes in the expression of ionic channels and 
reversal to a fetal gene program45. The ultimate result of this process is almost 
invariably the dilation of the LA45. According to Moe’s theory, AF termination is 
dependent on the statistical probability of all wavelets extinguishing simultaneously. 
This implies that in a larger LA more wavelets coexist, thus increasing the likelihood 
that AF will persist for longer periods.  
The classic aphorism “AF begets AF” has been widely used to describe the clinical 
evolution of this arrhythmia40.  
 
5.3.3 Contributing factors 
Tentative observations have suggested that autonomic nervous system activity may be 
implicated in the AF process46-51. It has been demonstrated that the onset and 
perpetuation of AF are preceded by variations in autonomic tone46. Specifically, it 
appears that a parasympathetic response increases vulnerability to AF and may elicit 
PV firing50, 51. These assertions are further supported by the promising results of 
catheter ablation aimed at the ganglionated plexi (GP)47-49. 
High circulating levels of inflammation markers, such as C-reactive protein and 
myeloperoxidase, are frequently found in AF patients, suggesting that there may be a 
correlation between AF and inflammation16, 45, 52-55. This association is also supported 
by the high incidence (up to 50%) of AF in patients undergoing cardiac surgery52, 54, 
56, 57. However, currently available data do not clarify whether inflammation is the 
cause or the consequence of AF. 
Finally, single and multiple gene mutations have been reported in families with a high 
burden of AF. Some of these genes codify for ion channel proteins (e.g. KCNx 
family) whilst others are implicated in intercellular connection (e.g. Connexin40)58, 59. 
Knowledge about AF genetics is growing rapidly. This new information will enhance 
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our understanding of AF mechanisms and may enable a genotype-based medicine to 
be developed60. 
 
5.4 CLINICAL IMPLICATIONS 
Common symptoms such as palpitations, fatigue, shortness of breath and dizziness are 
often correlated with the onset of AF. On the other hand, sustained AF episodes may 
lead to progressive deterioration of atrial and ventricular function that may culminate 
in overt congestive heart failure.  
Episodes of AF occur in >50% of patients with concomitant dysfunction of the sinus 
node (sick sinus syndrome) which suggests a causal relationship41, 61. Sick sinus 
syndrome is currently the most common indication (>50%) for permanent pacemaker 
implantation61, 62.  
Because of reduced blood flow in the LA and left atrial appendage (LAA), AF poses 
a serious risk of systemic embolization, particularly to the brain63. Patients at high risk 
(assessed by their CHADS2 or CHA2DS2VASC score) are therefore required to 
undergo systemic anticoagulation as a preventive measure against cerebrovascular 
accidents64, 65. Although stroke is the most feared complication of AF and results from 
major cerebral embolization events, some studies have suggested that micro-
embolization over time could be related to various degrees of dementia66, 67. 
Finally, data from the Framingham Study have showed that the presence of AF alone 
is associated with a 1.5 to 1.9-fold increase in risk of mortality68. 
 
5.5 CLASSIFICATION 
AF is classified according to the duration of the episodes: “paroxysmal” indicates 
recurrent AF episodes terminating spontaneously within seven days; “persistent” 
indicates AF lasting beyond seven days or requiring electrical or pharmacological 
cardioversion to be stopped; “longstanding persistent” indicates persistent AF lasting 
over one year5, 69. The term “non-paroxysmal”, although not included in the current 
guidelines, is commonly used to identify persistent and longstanding persistent AF. 
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Finally, the expression “permanent AF” identifies those patients in whom AF is 
accepted and restoration of the sinus rhythm (SR) will no longer be attempted5.  
 
5.6      THERAPEUTIC OPTIONS 
 
5.6.1 Direct current cardioversion 
Direct current cardioversion is often employed in the management of AF patients. 
Although the acute success of this intervention is excellent, recurrences of AF are 
very common (71%-84% at one year)5, 70, 71. 
Direct current cardioversion alone is of limited importance in the long-term 
management of AF patients. However it may be an important tool when used in 
combination with medical therapy or with catheter ablation5. 
 
5.6.2 Antiarrhythmic medications 
Antiarrhythmic drug (AAD) treatment has for several decades been the main 
treatment option for AF patients. All AADs currently available are flawed by their 
variable efficacy and by some degree of pro-arrhythmogenic effects5. 
AAD treatment can be employed in two different strategies: either aiming at 
controlling the ventricular rate (rate-control strategy), or at restoring and maintaining 
SR (rhythm-control strategy). In the AFFIRM study, over 4000 AF patients were 
randomized to either a rhythm-control or rate-control strategy and were followed for a 
median of 3.5 years. The rhythm-control group suffered higher mortality (although 
not statistically significant, p=0.08), more hospitalizations and more adverse events 
than the rate-control group72. However, a sub-analysis of the AFFIRM study 
suggested that in elderly patients the risk of drug adverse events may outweigh the 
benefit of a rhythm-control strategy. Moreover, they showed that the higher mortality 
in the rhythm-control group was mainly due to non-cardiovascular deaths73. The 
RACE study showed that rhythm-control therapy was associated with improvement of 
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the left ventricular function and a reduction in the left atrial diameter (LAD)74. 
Similarly, the SAFE-T study concluded that sustained SR was associated with an 
improved quality of life and exercise performance75. 
 
5.6.3 Surgery 
As cardiac surgery improved, more and more interest was focused on developing a 
surgical treatment for cardiac arrhythmias. After extensive testing on dog models in 
the mid-1980s, Cox managed to establish a surgical approach (Cox maze procedure) 
that could be employed in humans and that gave excellent results in both paroxysmal 
and non-paroxysmal AF21.  
Despite refinements in the technique, the Cox maze procedure remains highly 
invasive. Nowadays only AF patients who have to undergo cardiac surgery for other 
reasons (bypass graft, valve replacement, etc.) are considered as candidates for this 
operation69.  
In the last decade, off-pump techniques such as surgical AF ablation and the totally 
endoscopic AF ablation have been developed.  Pulmonary vein isolation (PVI) and 
LAA obliteration can be additionally performed in these procedures. However, the 
indications for and clinical importance of these new approaches are still unclear69. 
 
5.6.4 Catheter ablation 
In an attempt to offer a less invasive alternative to the Cox maze procedure, catheter 
ablation for AF was developed and promptly emerged as an additional therapeutic 
option. Following several randomized trials, it is now recognized that catheter 
ablation is superior to AADs in improving AF symptoms and quality of life76-78. 
Furthermore, a number of retrospective studies were able to show that AF-free 
patients following successful ablation are at similar risk of stroke and mortality as 
patients without AF79-81. However, a definite answer to whether catheter ablation 
improves stroke and mortality risk is still awaited and will probably follow the 
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completion of specifically designed multicenter, randomized trials such as the 
CABANA and EAST trials82, 83. 
 
5.6.5 Atrioventricular (AV) node ablation 
Symptomatic AF patients who are refractory to AADs and who do not qualify for AF 
ablation (because of exclusion criteria, poor prognosis or patient’s preference) can be 
referred to pacemaker implantation (preferably biventricular pacing devices) and 
subsequently to AV node ablation. In this brief procedure, the physiological AV 
conduction is permanently interrupted by means of catheter ablation84, 85. In this way, 
AF will continue in the atria, but the ventricular response will be regulated by the 
pacemaker. Previous studies demonstrated that this strategy can improve symptoms 
and increase left ventricular ejection fraction (LVEF) in selected patients86, 87. 
 
5.7 CATHETER ABLATION TECHNIQUES 
Catheter ablation is a percutaneous procedure in which catheters are advanced to the 
heart from a mini-invasive vascular access. The procedure is performed under 
fluoroscopic guidance and, more recently, assisted by a three-dimensional navigation 
system. Catheter ablation for AF can be performed using various energy sources (such 
as cryoenergy, ultrasound and laser) but radiofrequency is by far the most frequently 
used worldwide. Application of radiofrequency energy induces irreversible thermal 
damage in the myocardium thus preventing impulse formation and/or conduction in 
the targeted area.  
 
5.7.1 Trigger-based ablation 
Successful ablation aimed at focal sources of AF was first reported in 1994 by 
Haïssaguerre28. Following the definition of the important role of electrical activity 
arising from the PVs, focal ablation at these foci was initially attempted29. Modest 
outcomes and high incidence of PV stenosis following focal ablation led to the 
development of PVI procedures88, 89. This strategy was first performed with a 
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segmental approach, targeting the earliest site of activation (breakthrough) at the PV 
ostium90, 91. Later, Pappone introduced the circumferential approach, in which PVI 
was achieved by deploying circumferentially contiguous lesions at a distance ≥5 mm 
from the PV ostia (Figure 1)92. This purely anatomical approach provided satisfactory 
results with shorter procedures and an improved safety profile.  
PVI has now become the cornerstone of AF ablation. There is unanimous agreement 
that PVI represents the minimum endpoint for ablation of both paroxysmal and non-
paroxysmal AF69. Moreover, restored PV conduction can be demonstrated in the vast 
majority of patients admitted for a repeated ablation procedure93-95. Electrical 
reconnection of the PVs is believed to be the principal responsible mechanism for 
recurrences of AF. Finally, patients in whom extra-PV ectopies have been 
demonstrated can benefit by additional ablation targeting these foci31, 33, 34. 
 
 
Figure 1 – Posteroanterior view of the left atrium (reconstructed by the Carto3TM 
system), showing displacement of ablation lesions (red dots) for circumferential 
pulmonary vein (PV) isolation. LAA: left atrial appendage, LSPV: left superior PV, 
LIPV: left inferior PV, RIPV: right inferior PV, RSPV: right superior PV. 
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5.7.2 Substrate-based ablation  
Although stand-alone PVI has provided satisfactory clinical results in paroxysmal AF, 
its application appears to be insufficient in non-paroxysmal AF. With the exception of 
a minority of centers, there is agreement that in these patients there is a need to 
additionally target the substrate that is perpetuating the arrhythmia34, 69.  
Current strategies to modify AF substrate include linear ablation, complex 
fractionated electrogram (CFE) ablation, GP ablation and rotor ablation. 
The first report of curative catheter ablation for non-paroxysmal AF was presented by 
Swartz et al. in 1994, and consisted of a set of linear lesions in the LA96. In the same 
year, a similar approach with linear ablation targeting the RA was described by 
Haïssaguerre97. 
Although successful, linear ablation was initially restrained by the limited technology 
available and by a high rate of complications. Nowadays, several centers perform a 
roof line (connecting the left superior PV with the right superior PV) and a mitral 
isthmus line (from the inferior aspect of the left inferior PV to the MV annulus) as an 
adjunctive strategy to PVI (Figure 2)98. 
In the late 1990s, the presence of fractionated electrograms (later denominated CFEs) 
was first associated with areas of slow conduction and pivot points and believed to 
represent crucial regions for AF maintenance99. In an immunohistological study, CFE 
areas were found to represent enhanced tissue fibrosis with a reduced expression of 
gap junction proteins100. 
Involvement of CFE areas in AF maintenance is further supported by the clinical 
results following ablation aiming at these regions. Nademanee et al. established a new 
ablation approach by solely targeting CFE areas in paroxysmal and non-paroxysmal 
patients. AF termination was achieved in 95% of the patients and SR maintenance in 
91% at one year follow-up101. However, these results could not be reproduced by 
other centers. 
In spite of the questionable worth of stand-alone CFE ablation, adjunctive CFE 
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ablation to PVI is used by several centers in the treatment of non-paroxysmal AF 
(Figure 3)98.  
A combination of linear and CFE ablation is performed in the “stepwise approach”102, 
103. In this technique, ablation is aimed at sequential targets: PVI, superior vena cava 
and CS isolation, ablation at sites of complex electrical activity and finally roof and 
mitral lines. Previous reports have shown remarkable acute and long-term success 
following these extensive procedures102, 104, 105. Moreover, their authors were able to 
show that the order of the targets was irrelevant to the clinical outcomes, suggesting 
similar importance of all these mechanisms to the maintenance of AF103. 
 
 
Figure 2 – Anteroposterior view of the left atrium (reconstructed by the EnSite 
NavXTM system), showing displacement of ablation lesions for roof line (green dots 
between RSPV and LSPV) and mitral isthmus line (green dots between LIPV and the 
MV annulus). MV: mitral valve, other abbreviations as in Figure 1. 
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The epicardial localization of GPs makes them amenable to ablation. It is widely 
accepted that autonomic innervation is involved in the pathophysiology of AF. 
However, clinical outcomes from GP ablation, either alone or in combination with 
PVI, are not consistent and more research is needed to assess the importance of these 
targets in AF ablation47-49. 
Recent developments in mapping tools have led to the reconsideration of the localized 
source hypothesis whereby organized rotors may drive and maintain human AF. 
Narayan et al. employed custom software to map AF rotors and reported impressive 
outcomes following PVI and rotor ablation26. The results of ongoing multicenter trials 
may well produce more evidence in support of rotor mapping and ablation. 
 
 
Figure 3 – Right anterior oblique view of the left atrium (reconstructed by the EnSite 
NavXTM system), showing a complex fractionated electrogram map and displacement 
of ablation lesions (green dots) corresponding with areas of high fractionation (white 
and red color). Abbreviations as in Figures 1 and 2. 
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5.7.3 Procedural endpoints 
One of the factors contributing to the widespread use of PVI is its straightforward 
endpoint. Electrical conduction block from the LA to the PV is used by most centers 
to document PVI, and is considered a sufficient endpoint for paroxysmal AF 
ablation106. A small proportion of operators may employ additional pacing maneuvers 
to increase the specificity of PVI assessment107, 108. 
Conversely, catheter ablation in non-paroxysmal AF is currently restrained by 
undefined endpoints. AF termination, non-inducibility, conduction block over linear 
lesions, CFE abatement and the disappearance of vagal responses have all been 
utilized in clinical practice. While some of these endpoints are technically difficult to 
assess, others are flawed by a high degree of subjectivity and their clinical importance 
has yet to be confirmed109. 
 
5.7.4 Indications for atrial fibrillation ablation 
Catheter ablation is a therapeutic option that is currently considered only for 
symptomatic AF patients who are refractory or intolerant to at least one Class I or 
Class III AAD69. The latest HRS/EHRA/ECAS expert consensus statement suggests 
the following indications: 
      Paroxysmal AF: catheter ablation is recommended, class I, level of evidence A 
      Persistent AF: catheter ablation is reasonable, class IIa, level of evidence B 
      Longstanding persistent AF: catheter ablation may be considered, class IIb,  
      level of evidence B                                 
It is recognized that in certain cases, catheter ablation may also be regarded as first-
line therapy for AF. Finally, it is emphasized that such indications only apply if AF 
ablation is performed in experienced centers by appropriately trained 
electrophysiologists69. 
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5.7.5 Clinical outcomes 
The field of AF ablation has undergone a huge expansion in the past decade. In order 
to improve outcomes, new ablation techniques and technology have been developed.  
For several reasons, outcomes of AF ablation as retrieved from the literature have 
been inconsistent. As suggested by a recent meta-analysis, heterogeneity in outcomes 
may have its origin in differences between patient populations, ablation techniques, 
definitions of procedural success and follow-up monitoring modalities110. 
It is acknowledged that the outcomes of paroxysmal and non-paroxysmal AF should 
be considered separately, as they reflect two different stages of the disease69. In five 
randomized clinical trials in which PVI was compared to AAD treatment for 
paroxysmal AF, success rates of ablation ranged between 66% and 89% whereas 
AAD outcomes lay between 16% and 42%76-78, 111, 112.  
Recently, two independent studies (RAAFT-2 and MANTRA-PAF) compared in a 
randomized fashion AADs to catheter ablation as first-line therapy in patients with 
paroxysmal AF113, 114. The RAAFT-2 study concluded that patients undergoing 
catheter ablation experienced a lower rate of recurrences of AF than those 
administered AADs114. The MANTRA-PAF study, on the other hand, found no 
significant difference in the cumulative AF burden after a two-year follow-up113. 
Outcomes of non-paroxysmal AF are more controversial as there is no consensus on 
what should be the endpoint after successful PVI. Moreover, several ablation 
strategies are employed and the results are usually inconsistent between different 
centers115, 116. Stand-alone PVI is believed to be insufficient in these patients and 
clinical success is poor (20%)109, 116. Adjunctive roof and mitral linear ablation 
produces improved outcomes in patients with non-paroxysmal AF. Arya et al. 
reported a 12-months success rate of 75% while Willems et al. had a 69% success rate 
after a mean follow-up of 16 months109, 117. Adjunctive CFE ablation after PVI has 
also been shown to be beneficial with outcomes ranging from 56% to 94% in several 
single and multi-center trials118-120. Ultimately, a step-wise approach seems to confer 
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the best outcomes, with the proportion of AF-free patients lying between 79% and 
95%104, 121.  
Data from a worldwide survey on the efficacy of AF ablation reported a medium-term 
success rate of around 75% in paroxysmal AF and 64% in non-paroxysmal AF 
patients off all AADs122. 
 
5.7.6 Shortcomings 
Recurrences of arrhythmias 
Recurrences of arrhythmias following AF ablation are frequent. The most common 
arrhythmia to relapse is AF. A large-scale study revealed AF recurrence rates of 
31.5% in paroxysmal and 41.0% in non-paroxysmal AF patients123. Similar findings 
were demonstrated by other studies110, 124, 125. AF recurrences are most frequent in the 
mid-term (<1 year) but can also occur >3 years after the index procedure124, 126. 
Patients who experience multiple AF recurrences are often considered for a repeat 
ablation procedure. 
Recurrences of atrial tachycardia (AT) on the other hand, mostly occur during the first 
months following ablation and particularly in non-paroxysmal AF patients119, 127, 128. 
Occurrences of AT are believed to be mediated by catheter ablation itself and can 
significantly complicate the management of these patients129. These arrhythmias 
respond poorly to AAD and they usually lead to higher ventricular rates and more 
severe symptoms. A repeat dedicated ablation session is the most effective treatment 
for post-ablation AT. 
Complications 
Catheter ablation for AF may lead to a wide range of complications, some of which 
may be life-threatening. A worldwide survey incorporating over 16,000 patients and 
20,000 procedures reported an overall complication rate of 4.5%, with death 
occurring in 0.15% of the patients. The most common complications were cardiac 
perforation leading to cardiac tamponade (1.31%), neurological events (stroke or 
transient ischemic attack, 0.94%) and access-site vascular complications (1.47%)122. It 
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must be noted that this survey had a potential bias. Complication rates in the “real 
world” might be higher. Other known complications of AF ablation include PV 
stenosis, phrenic nerve damage and atrio-esophageal fistula, the latter being very rare 
but almost invariably fatal130.  
Finally, concerns have been raised for the remaining atrial functionality in those non-
paroxysmal AF patients who have undergone extensive ablation131. Preliminary 
results from an analysis of 40 patients after step-wise ablation suggest that in spite of 
significant scarring, left atrial functionality recovered in those who maintained SR105.  
Cost-effectiveness 
Despite the increasing enthusiasm for AF ablation, it must be reminded that the 
techniques are still under development and that these procedures may also increase 
the economic burden on healthcare systems. 
Compared to AAD treatment, AF ablation has a high initial cost. Canadian data 
estimated a total cost per AF ablation procedure of 9,590 C$. Another report 
suggested that AF ablation was cost-neutral compared to AAD, four years after the 
procedure132, 133. Similarly in the UK, AF ablation was found potentially cost-
effective if the benefits in terms of quality of life were maintained for five years134. 
Although these studies seem to favor AF ablation, it must be noted that they rely on 
the assumption that outcomes at 12 months are maintained until five years from the 
initial procedure. Moreover, these studies do not take into account that a significant 
proportion of patients continue AAD treatment after having undergone AF ablation 
thus leading to additional cost and risk of AAD side-effects135. A recent review 
concluded that the scientific evidence currently available (particularly in regard to 
hard endpoints) is insufficient to permit conclusions about the cost-effectiveness of 
AF ablation to be drawn135.  
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5.8 CURRENT CHALLENGES AND CONTROVERSIES OF AF 
ABLATION 
Challenging and unresolved aspects of AF ablation include patient selection, 
incomplete understanding of the mechanisms involved in AF and quality assurance of 
ablation lesions. 
Clinical outcomes of AF ablation can be very different from patient to patient. It is 
reasonable to suppose that improved patient selection would ameliorate ablation 
outcomes and avoid the risk of complications in individuals with a poor prognosis. 
The definition of pre-procedural parameters that can predict long-term outcomes is 
therefore an open issue in AF ablation.  
So far parameters such as age, gender, AF type, body mass index, LAD, LVEF, AF 
cycle length (AFCL), AF history, presence of diabetes, hypertension or other cardiac 
disease have been examined with widely variant results121, 123, 124, 136-139. Even 
echocardiographic measurement of LAD, a parameter which may depict the degree of 
remodeling of the LA, has not shown consistency between studies140-142. Moreover, 
these parameters may be related and act as reciprocal confounders. For this reason it 
could be worthwhile to define statistical models that allow such complex interactions 
to be taken into account.  
Although there is unanimous agreement on the importance of electrical activity 
arising from the PVs in triggering AF, the mechanisms that sustain the arrhythmia are 
poorly understood. This aspect is particularly relevant in non-paroxysmal AF patients 
in whom a trigger-based ablation (with stand-alone PVI) does not appear to be 
sufficient to guarantee satisfactory results109, 116. New insights into the 
pathophysiology of AF may allow the development of a mechanistic (rather than 
empirical) ablation strategy for non-paroxysmal AF patients. Such a strategy may 
enable us to obtain positive long-term outcomes with the minimum extent of 
collateral myocardial damage. A definition of precise procedural endpoints is also 
required to improve reproducibility between different centers.  
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Electrical reconnection of the PVs is often observed in AF patients who are accepted 
for a second ablation procedure93-95. A repeat PVI usually improves long-term results. 
Catheter ablation is mostly performed under fluoroscopic guidance. Although three-
dimensional navigation systems are extremely useful to the electrophysiologist, 
catheter stability and contact with the atrial wall are highly dependent on the 
experience and the tactile skills of the operator.  
Although this has never been formally demonstrated, it is believed that intermittent or 
poor contact during the first few seconds of ablation may result in the development of 
local myocardial edema that can hamper lesion transmurality143. Under such 
circumstances, the tissue is only partially damaged and the healing of the edema (a 
process that can take from hours to days) may restore electrical conduction (leading 
for instance to PV reconnection)144, 145.  
Proposed strategies to tackle this issue include pacing maneuvers, prolonged 
observation time, administration of steroids, isoproterenol or adenosine and improved 
catheter stability and contact31, 34, 106-108, 146, 147. The latter aspect is believed to be 
crucial. No matter what the ablation target is, good quality lesions are fundamental to 
obtaining the best results from catheter ablation95. Previous experimental work has 
shown that higher contact force (CF) leads to larger and deeper lesions148.  
In the past, parameters such as catheter tip temperature, electrogram voltage reduction 
and impedance fall (IF) have been used as surrogates for catheter-tissue contact to 
monitor lesion development149. Although useful, these parameters are flawed by 
various limitations which make their interpretation rather poor and unspecific. 
Recently, CF sensing ablation catheters, which allow accurate, quantitative 
measurement of the CF applied to the cardiac tissue, have been developed. Data from 
initial experience suggest that this technology is of great value, although further 
investigations are still needed to define and validate a safe and effective range of CF 
for clinical application94, 150-152.  
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6 Aims 
The aims of these studies were to investigate clinical results and technical aspects of 
AF ablation. 
 
1. To analyze long-term follow-up results and predictors of arrhythmia 
recurrence in a population of non-paroxysmal AF patients treated 
exclusively with a combined PVI + CFE ablation strategy. 
 
2. To determine the effects of intravenous flecainide on the distribution and 
extension of CFE areas in patients undergoing catheter ablation for non-
paroxysmal AF. 
 
3. To evaluate the relationship between catheter-to-tissue CF and IF during 
catheter ablation for AF. 
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7 Methods 
Patient Material 
These three studies included a total of 124 symptomatic AF patients that had 
previously attempted at least one AAD without success. Paper I and II involved only 
non-paroxysmal AF patients, while paper III involved mostly paroxysmal AF patients 
(94.3%) undergoing a first ablation procedure.  
The average age of the patients was 59±8 years. Females were in a minority (18/124, 
14.5%). Hypertension was common (51/124, 41.1%), but there was a low incidence of 
structural cardiac disease (17/124, 13.7%). The echocardiographic data indicated a 
tendency to LA enlargement although the LVEF was preserved (>45%) in all the 
patients. Beta-blocker was by far the most common class of AAD attempted.  
All patients underwent systemic anticoagulation with warfarin. An international 
normalized ratio value within the therapeutic range (>2.0) for at least four weeks was 
required before AF ablation. Detailed information about patient demographics is 
provided in each paper.  
Patients were referred to our institution from all over Norway. The study population 
was enrolled from the operation schedule. The studies were approved by the Regional 
Ethics Committee of Western Norway and were performed in accordance with the 
Declaration of Helsinki.  
Electrophysiological study and ablation set-up 
All the procedures included in the studies were performed at Haukeland University 
Hospital between 2007 and 2013. Conscious sedation with diazepam and morphine 
was used in all the patients and the procedures. Patients were admitted at the hospital 
one day prior to procedure, and warfarin was stopped two days before the procedure. 
Low molecular weight heparin was administered if necessary.  
Vascular access was obtained by puncturing the right and left femoral veins. Left 
atrial catheterization was performed via a transseptal puncture or via a patent foramen 
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ovale, where available. A 20-pole mapping catheter (Livewire™, St Jude Medical) 
was positioned in the RA with the distal poles in the CS. A 10-pole circular catheter 
(Lasso™, Biosense Webster or Optima™, St. Jude Medical) was inserted through a 
long sheath in the LA and was used to confirm PV isolation. Finally, an open-
irrigated ablation catheter (specific models are reported in each individual paper) was 
advanced in the LA through the same transseptal puncture as for the long-sheath and 
was used for mapping and ablation. 
A three-dimensional electroanatomical system (Carto3™, Biosense Webster or EnSite 
NavX™, St. Jude Medical) was employed in all the procedures for catheter navigation 
and for mapping purposes. An advanced recording system (Lab System Pro™, Bard 
Electrophysiology) was used to visualize and record intracardiac electrograms. 
Radiofrequency ablation was always delivered in a temperature-controlled mode at an 
irrigation flow-rate of 15-20 ml/min and a temperature cut-off of 50°C. Energy was 
generally delivered for 60 s at each location and the power was titrated to a maximum 
of 35W for PVI or 40W for cavotricuspid isthmus ablation. In paper III, power was 
limited to 30W.  
Ablation targets 
PVI was performed by ablating circumferentially, in a point-by-point pattern at the 
PV antra (1-2 cm proximally to the ostium). Entrance block (confirmed by the 10-pole 
circular catheter) was used as endpoint for PVI. Differential pacing from the LAA 
was used to confirm PVI in the left PVs. Patients in AF at the end of the procedure 
received a direct current cardioversion before sheath removal in order to document 
PVI in SR. 
CFE ablation was performed in non-paroxysmal AF patients targeting areas of highly 
fragmented potentials (CFE-mean<80 ms). Prior to ablation, a CFE map was created 
by the electroanatomical mapping system by sampling continuous recording from the 
distal electrode of the ablation catheter. In paper II, a second CFE map was collected 
before ablation but after administration of intravenous flecainide.  
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CFE mapping and ablation were performed in the LA in all patients. Additional 
mapping and ablation were delivered in the CS and RA in selected patients at the 
operator’s discretion. The endpoint of CFE ablation was the disappearance of 
fractionated electrograms. 
Linear ablation was performed exclusively to treat ATs. Activation mapping and 
entrainment pacing were employed to locate the critical isthmus. Endpoints of linear 
ablation were AT termination and, if possible, demonstration of conduction block 
across the line. 
A cavotricuspid isthmus line was performed in patients with a clinically documented 
history of typical atrial flutter. Bidirectional conduction block was the endpoint of 
cavotricuspid isthmus ablation. 
Follow-up 
Patients were monitored for 24 hours and usually discharged the day after the 
procedure under warfarin. Anticoagulation and AAD were continued for at least three 
months regardless of procedural outcome. All patients were followed up on an 
ambulatory basis at three, six and 12 months with clinical examination, ECG and 
echocardiography. Depending on arrhythmia recurrence and symptoms, medications 
were either discontinued or modified. After the first year, follow-up was performed in 
selected patients depending on the clinical situation.  
We defined “success” when patients remained completely arrhythmia-free after a 
blanking period of three months; “clinical improvement” when previously persistent 
AF patients had only occasional short episodes of self-terminating arrhythmia but 
great improvement of symptoms; “failure” when patients experienced recurrences of 
persistent arrhythmia. 
Paper I included repeated ablation procedures that were scheduled in 36 unsuccessful 
patients at least six months after the index procedure. In paper II clinical outcomes 
were evaluated only by considering the index procedure.  
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Data collection 
Data in paper I were retrieved from the procedural reports and from the patients’ 
medical journal.  
Data in paper II were retrieved from the three-dimensional navigation system (EnSite 
NavX). Every CFE mapping point was annotated on a pre-formatted form with the 
corresponding CFE-mean value, average electrogram amplitude and anatomical 
location. CFE and scar areas were measured by the system and expressed in cm2.  
Data in paper III were retrieved from the three-dimensional navigation system 
(Carto3). Qualified lesion points were selected according to specific enrolling criteria. 
CF and impedance data were registered automatically by the system. Anatomical 
location of points and force-direction angle were annotated on a pre-formatted form 
by a remote operator. 
Statistics 
Continuous variables were presented as mean ± standard deviation or as median and 
interquartile range when data did not follow a normal distribution. The Kolmogorov-
Smirnov test was used to confirm normal distribution of the data. Categorical 
variables were presented as percentages and compared by the chi-squared test. For 
comparison between continuous variables we used paired and unpaired t-tests, 
Wilcoxon signed-rank test and Mann-Whitney U test as appropriate. In paper III we 
used the Kruskal-Wallis test and the Friedman test as non-parametric alternatives for 
the analysis of variance. Associations between continuous variables were presented as 
rank correlations (Spearman's rho). Univariate and multivariate logistic regressions 
were used for predictor analysis. Optimal cut-offs for specific continuous predictors 
were determined by minimizing the distance from the optimal test in a receiver 
operating characteristic (ROC) curve. Statistical analysis was performed with SPSS 
Statistics for Windows, Version 19.0 (IBM Corp. 2010). All tests were two-tailed. A 
p-value <0.05 was considered to be statistically significant. 
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8 Results 
Paper I 
We studied 66 non-paroxysmal AF patients (mean age 58±9 years, 86% male) who 
underwent exclusively PVI + CFE ablation and were followed up for a mean of 
40±14 months. 
After the first ablation procedure, 21 (31.8%) patients were arrhythmia-free, 20 
(30.3%) displayed clinical improvement and 25 (37.9%) suffered recurrences of 
persistent atrial arrhythmias. After multiple procedures (112 in total, mean 1.7±0.7 
per patient), 38 (57.6%) patients were arrhythmia-free, 15 (22.7%) displayed clinical 
improvement and 13 (19.7%) suffered recurrences of persistent atrial arrhythmias. 
A total of five major complications were recorded (4.5%). Twenty-five patients 
(37.9%) developed AT following PVI + CFE ablation. In 12 cases a repeat ablation 
session was required to treat the AT. 
Thirty-six patients (54.5%) underwent multiple procedures. In all the repeat 
procedures, manifest electrical reconnection of one or more PVs was observed and 
additional PVI was therefore performed. All 12 of those who started the repeat 
procedure in SR and all 8 of those who started in AT displayed a procedural benefit, 
compared to 9 out of 16 of those who started the repeat procedure in persistent AF 
(p<0.05).  
Multivariate analysis revealed that female gender and duration of uninterrupted AF 
were independent predictors of long-term procedural failure (p=0.01 and 0.004 
respectively, OR 12.31 and 1.49 respectively). ROC analysis estimated an 
uninterrupted AF duration of 3.5 years as the optimal cut-off point for predicting 
procedural failure (sensitivity 85%, specificity 74%). 
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Paper II 
We enrolled 23 non-paroxysmal AF patients (mean age 59±7 years, 91% male) to 
study the effect of intravenous flecainide on the distribution and extension of CFE 
areas.  
Before flecainide administration, a CFE-mean value cut-off <120 ms resulted in CFE 
areas covering an average of 52.6±26.6% of the total LA surface. A lower CFE-mean 
cut-off resulted in a significantly smaller proportion of the CFE area.  
Following flecainide administration, the duration of the QRS complex was slightly 
but significantly prolonged (104±15 vs. 111±18 ms, p<0.001). The CFE-mean value 
increased in all patients, from an average of 111.5±55.3 ms to 132.3±65.0 ms 
(p<0.001). An analogous increase was found by separately analyzing each segment. 
AFCL in the LAA was similarly affected (155.1±20.8 vs. 195.0±27.1 ms, p<0.001). 
Overall, average atrial electrogram amplitude decreased significantly after flecainide 
administration (0.30±0.31 vs. 0.25±0.20 mV, p<0.001) as well as the electrogram 
amplitude measured in the LAA (0.96±0.68 vs. 0.64±0.34 mV, p<0.01). The area 
detected as scar by the system increased (1.6±4.2 to 4.2±6.6 cm2, p<0.01) in all 
patients following flecainide administration. Prolongation of CFE-mean values and 
abatement of electrogram amplitude led to a decrease in the extension of CFE areas. 
We observed a reduction of CFE area in all regions and in all the patients (average 
32.9%) after flecainide administration. We observed a large degree of spatial 
preservation of CFE areas following flecainide administration, with an average of 
80.9% of preserved CFE areas.  
A lower CFE-mean value was found in the portions of CFE areas that were preserved 
than in those that disappeared (73.8±17.4 vs. 89.4±17.1 ms; p<0.001). ROC analysis 
estimated a CFE-mean value of 78 ms as the best cut-off point for predicting the 
disappearance of CFE areas following flecainide administration (71% sensitivity, 
66% specificity). A higher electrogram amplitude was found in the preserved CFE 
portions compared to those that disappeared (0.37±0.28 vs. 0.28±0.20 mV; p<0.001).  
After a mean follow-up of 22.1±5.0 months, 65.2% of patients maintained stable SR. 
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Paper III 
We studied 35 AF patients (mean age 61±9 years, 80% male) to explore the 
relationship between catheter-to-tissue CF and IF during ablation.  
Average CF recorded was 9.0 g (IQR 9.0, total range 1-48 g). Higher CF and 
maximum IF were recorded in the right superior PV than in the left inferior (p<0.001) 
and left superior PV (p<0.05).  
Data points were allocated to five groups according to CF value. Group I included 
points with CF ranging from 1 to 5 g (n=107), Group II from 6 to 10 g (n=131), 
Group III from 11 to 15 g (n=76), Group IV from 16 to 20 g (n=36) and Group V for 
lesions exceeding 20 g (n=44). All the groups showed an acute IF in the first 10 s of 
ablation, followed by a plateau phase in Group I and by a progressive fall in the other 
groups. Maximum IF appeared at 50 s of ablation in Groups II, III and IV, and at 40 s 
in Group V. Group V showed a statistically significant rise in impedance during the 
last 20 s of ablation, from a median IF of 20.0 Ω to 15.0 Ω (p<0.01). 
Comparisons between the groups showed that levels of IF were statistically different 
(p<0.001) at each time point between all groups, except between Groups III and IV. 
Similar results were found for maximum IF. A linear correlation was demonstrated 
between maximum IF and CF (Spearman’s rho=0.54; p<0.01). 
Finally, we evaluated the impact of force-direction angle on CF and maximum IF. 
The median CF of the points with 0-30° (4.0 g) was significantly lower than those 
with 30-60° (11.0 g, p<0.001) and 60-135° (10.0 g, p<0.001). Similar results were 
also found for maximum IF (10.0 Ω, 15.0 Ω and 16.0 Ω) in lesions with force-
direction angles of 0-30°, 30-60° and 60-135° respectively (p<0.001).  
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9 General discussion 
The field of AF ablation has expanded significantly in recent years. Regarded as an 
experimental approach less than two decades ago, this treatment has now become a 
routine procedure69. Although it was initially developed for paroxysmal AF patients, 
catheter ablation is also increasingly used in the treatment of non-paroxysmal AF. In 
this subgroup of patients however, evidence is still scarce and controversial115, 116, 153. 
A multicenter randomized trial recently compared ablation and AAD in persistent 
AF154. At the end of the one-year follow-up, 70.4% of the patients in the ablation 
group were arrhythmia-free, compared to 43.7% in the AAD group. A similar single-
center non-randomized investigation reported an arrhythmia-free proportion of 76% 
in patients who underwent ablation versus 46% in those who were managed with 
AAD155. Patients receiving AAD were additionally more likely to undergo electrical 
cardioversion and to develop side-effects from their medications155. 
In spite of these encouraging findings, which favor the potential advantage of catheter 
ablation, the definition of clinical outcomes in non-paroxysmal AF has been more 
challenging than in paroxysmal AF116. Heterogeneity in patient selection, procedural 
strategy, technological equipment and follow-up may represent plausible causes of 
this lack of consistency115, 153. 
 
9.1   Patient selection: a key to improving clinical outcomes of non-paroxysmal AF 
ablation  
It is recognized that non-paroxysmal AF represents a highly heterogeneous group of 
patients in terms of symptoms and cardiac comorbidities. Patient selection in non-
paroxysmal AF is therefore an important variable in the assessment of clinical 
outcomes of catheter ablation35. In the above-mentioned work by Mont et al., the 
inclusion of relatively young and healthy AF patients may have contributed 
substantially to the final outcomes154. 
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Several parameters have been previously investigated as potential predictors of long-
term outcomes but the results are inconsistent117, 121, 123, 136, 138, 139, 156-158. In paper I, we 
showed that the duration of uninterrupted AF was a strong predictor of AF 
recurrence.  While clinical outcomes were satisfactory with an AF duration ≤4 years, 
poor results were obtained in patients with an AF duration >4 years. Although the 
duration of uninterrupted AF has previously been reported as a potential predictor, 
some authors have suggested an AF duration <2 years as a prudent indication for AF 
ablation137, 139, 156, 158. Larger studies are needed to clarify this discrepancy and to 
define an ideal AF duration cut-off as inclusion criteria for non-paroxysmal AF 
ablation. 
Because of the propensity of AF to self-perpetuation, AF duration and left atrial size 
might be closely correlated. In paper I we did not find any association between LAD 
and long-term outcomes. Contrasting findings suggest that echocardiographic 
measurement of LAD does not represent an accurate estimate of real LA size140, 142, 
159. Some authors have suggested that other measurements such as LA sphericity or 
LA volume obtained from magnetic resonance (MR) scans may be more reliable 
indicators of AF remodeling140, 144, 159.  
MR has also recently been employed to quantify fibrosis in the LA35, 160. Preliminary 
reports have shown that a lower amount of fibrosis yields to better long-term 
outcomes after catheter ablation35, 160. This new information suggests that atrial 
remodeling not only contributes to the perpetuation of AF but may also limit the 
efficacy of curative AF ablation. Most interestingly, it has been demonstrated that the 
remodeling process can be stopped and reversed by the presence of SR, and that 
measures that aim to restore SR before ablation may have positive effects on the long-
term outcomes142, 161-164.  
In paper I we also observed that females had significantly poorer prognoses than 
males. This finding has been previously shown, although inconsistently, and the 
reasons are unclear138, 165. The prevalence of extra-PV foci seems to be higher in 
females. Extra-PV foci mapping and ablation can be challenging and are not routinely 
performed32, 163, 164, 166. A number of authors have additionally observed that female 
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AF patients are managed less aggressively than their male counterparts in terms of 
AADs and direct current cardioversions. When finally offered catheter ablation, 
female patients are subject to a delayed referral to this procedure possibly with more 
advanced stages of atrial remodeling157, 166. Finally, in paper II we reported that 
female patients manifested by far the lowest proportion of CFE area in the LA (<5%). 
This observation may support the hypothesis that the AF substrate could be different 
in females and males. If this is the case, future AF ablation techniques could be 
specifically tailored to female patients.  
 
9.2   Procedural strategy: PVI+CFE ablation is a plausible approach for non- 
paroxysmal AF 
An additional factor complicating the comparison of clinical trials for non-
paroxysmal AF is the variety of ablation strategies employed. Most authors agree that 
stand-alone PVI is not sufficient in non-paroxysmal AF69. Linear and CFE ablation 
are currently widely employed as adjunctive strategies although it is not yet clear 
which provides the best results. The results from the multicenter, randomized, STAR-
AF II trial may throw light on this issue120.  
In paper I we showed that a procedural strategy consisting exclusively of PVI plus 
adjunctive CFE ablation led to satisfactory long-term results in a mixed population 
with persistent and long-standing persistent AF. After multiple procedures and an 
average follow-up of over three years, 80.3% of the patients enjoyed clinical benefits 
from the treatment including 57.6% that remained arrhythmia-free. 
Ablation of CFE areas is an accepted strategy, albeit controversial, for the treatment 
of non-paroxysmal AF. The conflicting results described in the literature could 
originate from a lack of consensus regarding the definition of CFE, mapping 
technique or ablation endpoint167-169.  
In localizing CFE areas for instance, dedicated CFE mapping tools are employed by 
some centers while others only use “visual inspection”. Moreover, there is no 
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agreement regarding what should be the endpoint of CFE ablation; AF termination, 
CFE disappearance and CFE organization have all been adopted101, 118, 119, 170, 171.  
These incongruences affect not only clinical results but also the safety profile and 
duration of these procedures. As shown in paper II, CFE areas are widespread and, 
according to the criteria used, may cover >50% of the LA surface. In order to abolish 
all these areas, extensive ablation must be performed, with potentially increased 
procedural time and risk of complications119, 128, 167, 172.  
Arguments in support of CFE ablation include the high degree of stability of CFE 
areas, frequent occurrence of AFCL prolongation or AF termination during targeting 
of these areas and plausible mechanistic association with the AF substrate. 
The temporal and spatial stability of CFE areas is crucial to prove any involvement of 
these regions with the substrate maintaining AF. A complete lack of stability on the 
other hand, would suggest that CFEs originate from passive atrial activation and that 
their role in AF is only functional173, 174. In paper II we demonstrated a high degree of 
spatial and temporal stability of CFE areas. Over 80% of CFE areas registered 40 
minutes after flecainide administration were localized within the spatial limits of 
previously mapped CFE areas. Although conflicting data concerning CFE stability 
have been published, the semi-automated measurements performed in our study may 
strengthen our results as well as the consistency of our findings among patients.  
Several authors reported that changes in AF (prolongation of AFCL or termination 
into AT or SR) occur frequently during CFE ablation101, 118, 119, 175, 176. Such acute 
changes may suggest that ablation targeting these areas does in fact affect the 
substrate maintaining AF. In paper I we reported an acute termination of AF into SR 
in 36.6% of the procedures during CFE ablation, either directly from AF or via AT. 
However, it should be remembered that the mechanism by which CFE ablation 
contributes to changes in AF is still unclear.  
Finally, CFEs were originally linked to areas of fibrosis that may have represented 
pivot points of rotors perpetuating AF99, 101, 118. The wide distribution of CFEs in 
patients with persistent and long-standing persistent AF could be a consequence of an 
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increased amount of fibrosis due to AF remodeling100. Some reports have also shown 
that CFE areas are characterized by lower electrogram amplitude than non-CFE 
areas177. However, discordant results concerning the relationship between CFE and 
fibrosis are reported in the literature27, 178. Recently, Jadidi et al. investigated the 
correlation between fibrosis and CFEs using delayed enhancement MR and found that 
41% of continuous CFE areas were found in regions of “patchy fibrosis” and 11% in 
regions of dense fibrosis, while the majority (48%) were found in areas of healthy 
tissue178. These interesting results add to previously published data and prove that at 
least some CFEs are functional and represent unspecific targets for ablation176, 179, 180. 
It has been suggested that, if CFE ablation is pursued, it would be of importance to 
distinguish between culprit and functional CFEs180. 
In paper II we showed that intravenous flecainide can be administered in order to 
partially eliminate functional CFE, estimated to be more than 30% and to highlight 
culprit CFE. A CFE-mean cut-off of 80 ms may facilitate the identification of stable 
CFE areas. Long-term outcomes of ablation targeting exclusively CFE areas after 
flecainide and with a CFE-mean <80 ms were comparable to previous studies, thus 
supporting that disappeared areas are functional169. 
The implementation of these two measures in clinical practice could greatly reduce 
the amount of atrial myocardium targeted for CFE ablation with potentially great 
benefit for procedural safety. It has in fact been suggested that extensive ablation in 
the LA may bring a higher risk of complications and increase the incidence of post-
ablation ATs181, 182. 
 
9.3   Technological advances: contact force monitoring  
The main limitation of radiofrequency catheter ablation today is the unpredictable 
formation and endurance of its lesions. Although it has not been formally 
demonstrated, there is agreement that poor lesion quality leads to a transient effect 
and may eventually result in arrhythmia recurrences143, 149. 
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Experimental studies have shown that sub-optimal CF is associated with inadequate 
lesion formation148, 149. Following the availability of CF-sensing catheters, a great deal 
of research has been focusing on this topic94, 95, 150-152, 183-186. 
Previous studies have shown how CF varies significantly in different locations in the 
LA. Lower degrees of CF are achieved in the left PVs and particularly in the left 
superior PV94, 184. These observations may explain the difficulty of isolating the left 
superior PV and the frequent occurrence of its electrical reconnection.  
Several investigations have also sought to validate the utility of this technology in 
assessing lesion development; IF has often been selected as the parameter of 
comparison for this purpose93, 184-187. In paper III we demonstrated a significant 
association between catheter tip-to-tissue CF and IF. Although other authors have 
confirmed our results, the correlation coefficient (Spearman’s rho=0.54) found in 
paper III between CF and IF was higher than had been observed in similar studies184, 
187. The reasons for this difference may be found in the rigorous selection of qualified 
points in our study based on a strict assessment of catheter stability. In this light, the 
results of paper III acquire additional significance, and suggest that CF plays an even 
more important role when employed together with improved catheter stability. This 
supposition is confirmed by the positive effects of adopting a steerable sheath (a tool 
that potentially improves catheter stability) to support the ablation catheter during AF 
ablation117, 188.  
Recently, findings from preliminary studies on CF technology have been used to 
develop annotation algorithms that may improve real-time assessment of lesion 
quality. A recent study investigated the clinical benefits of an algorithm that validates 
only ablation points characterized by an IF >5% and by a catheter movement <2 mm. 
When applied to AF ablation, these parameters led to a significant reduction in acute 
PV reconnection and a higher (although not statistically significant) proportion of 
arrhythmia-free patients93.  
Impedance monitoring has also previously been used in the prevention of acute 
complications. Under stable catheter conditions, a sudden rise in impedance during 
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ablation may be observed ahead of steam pops or thrombus formation, and indicates 
that energy delivery should cease189. The results of paper III show that a high CF (>20 
g) may lead to a late impedance rise occurring after 40 s of ablation; this underlines 
the fact that procedural safety may benefit from the constant monitoring of CF and IF. 
Controlling CF or alternatively, reducing ablation duration when a high CF is 
obtained, may curtail the incidence of complications. 
 
9.4   Follow-up considerations: definition of clinical endpoints and impact of 
arrhythmia recurrences after ablation  
The latest expert consensus document draws attention to the importance of 
standardized follow-up routines for the evaluation of clinical trials involving AF 
patients. Total freedom from atrial arrhythmia in the absence of AAD is the most 
objective definition of success and should be the preferred endpoint for all AF 
ablation trials69. In a clinical setting, however, this may be difficult to achieve in non-
paroxysmal AF patients. 
Recently, Tondo et al. have shown that 46% of patients after ablation experienced AF 
recurrences that were completely asymptomatic190. Other reports have underlined how 
quality of life improves significantly with the reduction of AF burden, even when AF 
recurs191, 192. Finally, AADs can reduce significantly AF recurrences after catheter 
ablation118, 193, 194. How should these outcomes be considered in a clinical setting?  
The current guidelines state that referral to catheter ablation is mainly dependent on 
the presence of symptomatic AF69. This thus acknowledges that the disappearance or 
improvement of AF symptoms should be regarded as satisfactory outcomes69, 190, 191.  
In paper I, besides the 57.6% of patients who remained arrhythmia-free after the 
procedure, a further 22.7% had significant improvement of their symptoms. Most of 
these patients remained in stable SR for a long time and later experienced episodes of 
self-terminating paroxysmal AF. 
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An additional issue concerns the intensity of the follow-up after ablation. Martinek et 
al. showed that the proportion of arrhythmia-free patients fell with the implementation 
of more sensitive tools for arrhythmia detection195. 
Patients included in paper I were followed up for an average of over three years with 
Holter recordings, ECG and clinical examination. A stricter follow-up was employed 
in the first year from the ablation, with visits at three, six and 12 months. The 
intensity of further follow-up depended on the clinical situation. 
Previous studies have shown that recurrences of arrhythmia following AF ablation are 
most common in the first 12 months but may occur up to three years following 
ablation123-125. Recurrences of AF after ablation also seem to appear more often in 
non-paroxysmal AF patients110, 124, 125. The results of paper I confirm these findings: 
while recurrences occurred during the first 12 months in 42 patients (63.6%), only 
three (4.5%) suffered late recurrences (>12 months) up to 40 months from the initial 
procedure. Although rare, the development of very late recurrences raises a dilemma 
on the safety of discontinuing anticoagulation in those patients at high 
cerebrovascular risk.  
With regard to late arrhythmia recurrences, it is also of interest to consider AT and 
AF separately. Previous work has suggested that when AF is the clinical arrhythmia 
that recurs in the follow-up, PV reconnection may be the main mechanism involved93-
95, 146. In paper I, all the patients who underwent a repeat procedure had signs of 
reconnection of at least one PV. This is consistent with other observations125, 196.  
Recurrences of AT are relatively more frequent among non-paroxysmal AF 
patients119, 127, 128. It has been reported that the incidence of AT is linked to the 
extension of ablation performed in the LA129, 181. It is not clear which ablation strategy 
produces the highest risk of developing AT 119, 167. When linear ablation is chosen as 
the procedural strategy, post-ablation ATs are often characterized by a macro-reentry 
caused by recovered conduction over the lines129. When CFE areas are targeted, post-
ablation ATs can be characterized by either a macro- or a micro-reentry caused by 
areas of extremely slow conduction197, 198.  
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Post-ablation ATs may complicate the management of non-paroxysmal AF patients, 
but at the same time, they could also be regarded as a favorable prognostic factor. 
Although this often requires an extra procedure, mapping and ablation of AT is 
feasible. Patients who have undergone a repeat ablation session because of AT have a 
better long-term prognosis than those with a repeat ablation because of recurrences of 
AF127, 199.  Results from paper I show that all the patients (100%) who underwent a 
repeat ablation procedure because of AT had clinical improvement at follow-up 
compared with only 56% of those whose repeat ablation was due to persistent AF. 
It thus appears reasonable to suggest that AT should not be regarded as a 
complication but as an encouraging step towards stable SR. Future research should be 
addressed to the improvement of mapping techniques in order to facilitate ablation 
treatment of these arrhythmias. 
 
Study limitations 
Our results come from three single-center, non-randomized studies in which no 
control group was employed. The number of patients involved, especially females, 
was relatively small. However, this is consistent with previous literature and reflects 
the actual proportion of female patients referred for catheter ablation. 
Paper I was a retrospective study and, because of the follow-up protocol, we realize 
that some asymptomatic recurrences of arrhythmia may have been underestimated.  
In paper II, the study material was retrieved only from the LA. Conclusions therefore 
cannot be extrapolated to the PVs, RA and CS. 
In paper III, there were significant differences between the number of points in the 
different CF groups. Obtaining stable catheter contact is more challenging when high 
CF is applied and these differences probably express this difficulty. 
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10 Conclusions 
 
1. After long-term follow-up, a strategy of combined PVI + CFE ablation seems 
to provide a reasonable rate of arrhythmia-freedom and clinical improvement 
in non-paroxysmal AF patients. Patients with uninterrupted AF duration ≤ 4 
years appear to benefit most from this ablation strategy. Female gender and 
longer duration of uninterrupted AF are predictors of long-term failure. 
 
 
2. Flecainide reduces the extension of CFE areas in non-paroxysmal AF patients 
by slowing atrial conduction velocity and diminishing complexity and 
amplitude of atrial electrograms. CFE areas appear to be spatially and 
temporally stable after flecainide administration. These findings may influence 
approaches to CFE ablation and reduce ablation time and procedural duration. 
 
 
3. IF correlates significantly with catheter tip-tissue CF level during 60 s of 
ablation. CF exceeding 5 g produces greater IF, which probably indicates 
adequate lesion formation. CF greater than 20 g may lead to late tissue 
overheating. 
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